$NWBO
NORTHWEST BIOTHERAPEUTICS INC

2023 Q4 Form 10-Q Financial Statement

#000141057823002304 Filed on November 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $445.0K $406.0K
YoY Change -25.46% 97.09%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.133M $7.030M
YoY Change -13.69% -13.53%
% of Gross Profit
Research & Development $7.454M $7.201M
YoY Change -20.3% -6.41%
% of Gross Profit
Depreciation & Amortization $425.0K $410.0K
YoY Change 33.65% 32.26%
% of Gross Profit
Operating Expenses $15.59M $7.201M
YoY Change -16.98% -6.41%
Operating Profit -$13.83M
YoY Change -11.48%
Interest Expense -$1.000K $1.670M
YoY Change -99.99% 10.45%
% of Operating Profit
Other Income/Expense, Net -$2.021M -$4.755M
YoY Change -72.41%
Pretax Income -$18.92M -$18.58M
YoY Change -33.14% -43.44%
Income Tax
% Of Pretax Income
Net Earnings -$19.26M -$18.58M
YoY Change -31.94% -43.44%
Net Earnings / Revenue -4328.09% -4576.35%
Basic Earnings Per Share -$0.02
Diluted Earnings Per Share -$0.02 -$0.02
COMMON SHARES
Basic Shares Outstanding 1.154B 1.121B
Diluted Shares Outstanding 1.134M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.126M $6.100M
YoY Change -69.48% -35.28%
Cash & Equivalents $2.126M $6.097M
Short-Term Investments
Other Short-Term Assets $1.999M $1.750M
YoY Change -18.74% -25.18%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $4.125M $8.452M
YoY Change -56.23% -28.15%
LONG-TERM ASSETS
Property, Plant & Equipment $17.28M $16.75M
YoY Change 28.77% 27.62%
Goodwill $626.0K $626.0K
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $361.0K $357.0K
YoY Change 4.64% 5.31%
Total Long-Term Assets $23.74M $23.04M
YoY Change 8.41% 19.17%
TOTAL ASSETS
Total Short-Term Assets $4.125M $8.452M
Total Long-Term Assets $23.74M $23.04M
Total Assets $27.87M $31.49M
YoY Change -11.04% 1.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $13.79M $17.05M
YoY Change -21.85% 22.09%
Accrued Expenses $314.0K $370.0K
YoY Change -11.3% 10.78%
Deferred Revenue
YoY Change
Short-Term Debt $3.765M $3.450M
YoY Change 2688.89%
Long-Term Debt Due $16.72M $18.45M
YoY Change 8.52% -8.51%
Total Short-Term Liabilities $45.20M $49.22M
YoY Change -64.13% -57.61%
LONG-TERM LIABILITIES
Long-Term Debt $20.31M $11.04M
YoY Change 239.04% 85.8%
Other Long-Term Liabilities $9.404M $8.680M
YoY Change 115.19% 110.07%
Total Long-Term Liabilities $29.72M $19.72M
YoY Change 186.81% 95.77%
TOTAL LIABILITIES
Total Short-Term Liabilities $45.20M $49.22M
Total Long-Term Liabilities $29.72M $19.72M
Total Liabilities $74.92M $68.95M
YoY Change -45.06% -45.37%
SHAREHOLDERS EQUITY
Retained Earnings -$1.360B -$1.341B
YoY Change 4.83% 5.67%
Common Stock $1.292B $1.272B
YoY Change 10.85% 10.29%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$65.77M -$65.12M
YoY Change
Total Liabilities & Shareholders Equity $27.87M $31.49M
YoY Change -11.04% 1.27%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$19.26M -$18.58M
YoY Change -31.94% -43.44%
Depreciation, Depletion And Amortization $425.0K $410.0K
YoY Change 33.65% 32.26%
Cash From Operating Activities -$16.96M -$13.92M
YoY Change 91.63% -13.64%
INVESTING ACTIVITIES
Capital Expenditures $417.0K $440.0K
YoY Change -80.69% -259.42%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$417.0K -$440.0K
YoY Change -80.69% 59.42%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 14.42M 17.12M
YoY Change 27.02% 5.12%
NET CHANGE
Cash From Operating Activities -16.96M -13.92M
Cash From Investing Activities -417.0K -440.0K
Cash From Financing Activities 14.42M 17.12M
Net Change In Cash -2.956M 2.760M
YoY Change -964.33% -2655.56%
FREE CASH FLOW
Cash From Operating Activities -$16.96M -$13.92M
Capital Expenditures $417.0K $440.0K
Free Cash Flow -$17.37M -$14.36M
YoY Change 57.82% -9.35%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001072379
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Security Exchange Name
SecurityExchangeName
NONE
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1068400000
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1145100000
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35737
dei Entity Registrant Name
EntityRegistrantName
NORTHWEST BIOTHERAPEUTICS, INC
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
94-3306718
dei Entity Address Address Line1
EntityAddressAddressLine1
4800 Montgomery Lane
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 800
dei Entity Address City Or Town
EntityAddressCityOrTown
Bethesda
dei Entity Address State Or Province
EntityAddressStateOrProvince
MD
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20814
dei City Area Code
CityAreaCode
240
dei Local Phone Number
LocalPhoneNumber
497-9024
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
NWBO
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1153846907
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6097000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6965000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1745000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2460000
CY2023Q3 nwbo Share Receivable Current
ShareReceivableCurrent
610000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
8452000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
9425000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16751000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13418000
CY2022Q4 nwbo Constructions In Progress Net
ConstructionsInProgressNet
2028000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4014000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4189000
CY2023Q3 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
1292000
CY2022Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
1292000
CY2023Q3 us-gaap Goodwill
Goodwill
626000
CY2022Q4 us-gaap Goodwill
Goodwill
626000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
357000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
345000
CY2023Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
23040000
CY2022Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
21898000
CY2023Q3 us-gaap Assets
Assets
31492000
CY2022Q4 us-gaap Assets
Assets
31323000
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
12331000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
10687000
CY2023Q3 nwbo Accounts Payable And Accrued Liabilities Related Parties Current
AccountsPayableAndAccruedLiabilitiesRelatedPartiesCurrent
4716000
CY2022Q4 nwbo Accounts Payable And Accrued Liabilities Related Parties Current
AccountsPayableAndAccruedLiabilitiesRelatedPartiesCurrent
6955000
CY2023Q3 nwbo Convertible Notes Payable Net Current
ConvertibleNotesPayableNetCurrent
3451000
CY2022Q4 nwbo Convertible Notes Payable Net Current
ConvertibleNotesPayableNetCurrent
135000
CY2023Q3 nwbo Convertible Notes At Fair Value Current
ConvertibleNotesAtFairValueCurrent
10250000
CY2023Q3 us-gaap Notes Payable Current
NotesPayableCurrent
8198000
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
15403000
CY2023Q3 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
8882000
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
8668000
CY2023Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1019000
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
80559000
CY2023Q3 us-gaap Deferred Compensation Share Based Arrangements Liability Current
DeferredCompensationShareBasedArrangementsLiabilityCurrent
7000
CY2022Q4 us-gaap Deferred Compensation Share Based Arrangements Liability Current
DeferredCompensationShareBasedArrangementsLiabilityCurrent
2566000
CY2022Q4 nwbo Share Liability
ShareLiability
678000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
369000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
354000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
49223000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
126005000
CY2023Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
11038000
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
5991000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4134000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4370000
CY2023Q3 nwbo Contingent Payment Obligation Noncurrent
ContingentPaymentObligationNoncurrent
4550000
CY2023Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
19722000
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
10361000
CY2023Q3 us-gaap Liabilities
Liabilities
68945000
CY2022Q4 us-gaap Liabilities
Liabilities
136366000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1700000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1700000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1145100000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1068400000
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
1145000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1068000
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1271327000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1164885000
CY2023Q3 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
79000
CY2022Q4 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
79000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1340802000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1297122000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
3290000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
3145000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-65119000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-128103000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31492000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31323000
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
406000
CY2022Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
206000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1487000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1086000
CY2023Q3 us-gaap Revenues
Revenues
406000
CY2022Q3 us-gaap Revenues
Revenues
206000
us-gaap Revenues
Revenues
1487000
us-gaap Revenues
Revenues
1086000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7201000
us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-145000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7694000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20276000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26159000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7030000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8130000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21577000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23930000
CY2023Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
14231000
CY2022Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
15824000
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
41853000
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
50089000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13825000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-15618000
us-gaap Operating Income Loss
OperatingIncomeLoss
-40366000
us-gaap Operating Income Loss
OperatingIncomeLoss
-49003000
CY2023Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-112000
CY2022Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-12169000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
3875000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-15883000
CY2023Q3 nwbo Fair Value Adjustment Of Share Receivable
FairValueAdjustmentOfShareReceivable
487000
nwbo Fair Value Adjustment Of Share Receivable
FairValueAdjustmentOfShareReceivable
534000
CY2023Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1768000
CY2022Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-456000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-3648000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-156000
CY2023Q3 us-gaap Interest Expense
InterestExpense
1670000
CY2022Q3 us-gaap Interest Expense
InterestExpense
1512000
us-gaap Interest Expense
InterestExpense
3999000
us-gaap Interest Expense
InterestExpense
4847000
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-1692000
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-3097000
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-76000
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-6845000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4755000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-17234000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3314000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-27731000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-18580000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-32852000
us-gaap Net Income Loss
NetIncomeLoss
-43680000
us-gaap Net Income Loss
NetIncomeLoss
-76734000
CY2023Q3 nwbo Deemed Dividend Related To Warrant Modification
DeemedDividendRelatedToWarrantModification
519000
nwbo Deemed Dividend Related To Warrant Modification
DeemedDividendRelatedToWarrantModification
1433000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19099000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-32852000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-45113000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-76734000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-1397000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-2773000
us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-5956000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17702000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30079000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-44968000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-70778000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.08
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1134359
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1040982
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1106111
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1001703
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1134359
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1040982
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1106111
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1001703
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-61034000
CY2023Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
2974000
CY2023Q3 nwbo Value Of Warrants Exercised For Cash
ValueOfWarrantsExercisedForCash
32000
CY2023Q3 nwbo Stock And Warrants Issued During Period Value Conversion Of Debt And Accrued Interest
StockAndWarrantsIssuedDuringPeriodValueConversionOfDebtAndAccruedInterest
7920000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1565000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-18580000
CY2023Q3 nwbo Adjustments To Additional Paid In Capital Warrants Modification
AdjustmentsToAdditionalPaidInCapitalWarrantsModification
1126000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
519000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1397000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-65119000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-91666000
CY2022Q3 nwbo Value Of Warrants Exercised For Cash
ValueOfWarrantsExercisedForCash
430000
CY2022Q3 nwbo Adjustments To Additional Paid In Capital Reclassification
AdjustmentsToAdditionalPaidInCapitalReclassification
2402000
CY2022Q3 nwbo Adjustments To Additional Paid In Capital Reclassification Of Warrant Liabilities Related To Cashless Warrants Exercise
AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiabilitiesRelatedToCashlessWarrantsExercise
1421000
CY2022Q3 nwbo Stock And Warrants Issued During Period Value Conversion Of Debt And Accrued Interest
StockAndWarrantsIssuedDuringPeriodValueConversionOfDebtAndAccruedInterest
5281000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3361000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-32852000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
2773000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-108850000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-128103000
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
6536000
nwbo Value Of Warrants Exercised For Cash
ValueOfWarrantsExercisedForCash
2801000
nwbo Adjustments To Additional Paid In Capital Reclassification Of Warrant Liabilities To Stockholders Deficit
AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiabilitiesToStockholdersDeficit
76258000
nwbo Stock And Warrants Issued During Period Value Conversion Of Debt And Accrued Interest
StockAndWarrantsIssuedDuringPeriodValueConversionOfDebtAndAccruedInterest
17484000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2673000
us-gaap Net Income Loss
NetIncomeLoss
-43680000
nwbo Adjustments To Additional Paid In Capital Warrants Modification
AdjustmentsToAdditionalPaidInCapitalWarrantsModification
2200000
us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
1433000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
145000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-65119000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-123991000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9689000
nwbo Value Of Warrants Exercised For Cash
ValueOfWarrantsExercisedForCash
9986000
nwbo Adjustments To Additional Paid In Capital Reclassification
AdjustmentsToAdditionalPaidInCapitalReclassification
22090000
nwbo Adjustments To Additional Paid In Capital Reclassification Of Warrant Liabilities Related To Cashless Warrants Exercise
AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiabilitiesRelatedToCashlessWarrantsExercise
26800000
nwbo Stock And Warrants Issued During Period Value Conversion Of Debt And Accrued Interest
StockAndWarrantsIssuedDuringPeriodValueConversionOfDebtAndAccruedInterest
7613000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9741000
us-gaap Net Income Loss
NetIncomeLoss
-76734000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
5956000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-108850000
us-gaap Net Income Loss
NetIncomeLoss
-43680000
us-gaap Net Income Loss
NetIncomeLoss
-76734000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1101000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
934000
nwbo Amortization Of Debt Discount
AmortizationOfDebtDiscount
2006000
nwbo Amortization Of Debt Discount
AmortizationOfDebtDiscount
2111000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
3875000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-15883000
nwbo Fair Value Adjustment Of Share Receivable
FairValueAdjustmentOfShareReceivable
534000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-3648000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-156000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
211000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
184000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
2833000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
9741000
nwbo Warrant Modifications Associated With Convertible Notes Under Fair Value Option
WarrantModificationsAssociatedWithConvertibleNotesUnderFairValueOption
287000
us-gaap Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
5677000
us-gaap Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
29009000
nwbo Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
-802000
nwbo Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
310000
nwbo Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
13000
nwbo Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
-633000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
2657000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
1251000
us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
-2239000
us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
2127000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
117000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
98000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-36679000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-43926000
us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
3019000
us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
742000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3019000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-742000
nwbo Proceeds From Issuance Of Redeemable Convertible Preferred Stock By Common Stock Warrant Exercise Net Of Debt Redemption
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockByCommonStockWarrantExerciseNetOfDebtRedemption
52000
nwbo Proceeds From Issuance Of Capital Stock And Warrants
ProceedsFromIssuanceOfCapitalStockAndWarrants
9465000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1598000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
9986000
nwbo Proceeds From Investor Advance
ProceedsFromInvestorAdvance
7000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
10000000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
5600000
nwbo Proceeds From Issuance Of Convertible Notes Payable
ProceedsFromIssuanceOfConvertibleNotesPayable
12699000
nwbo Proceeds From Contingent Payment Obligation
ProceedsFromContingentPaymentObligation
4550000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
210000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
5390000
nwbo Repayment Of Investor Advances
RepaymentOfInvestorAdvances
200000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
38343000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
30617000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
487000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8307000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-868000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5744000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6965000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15169000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6097000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9425000
nwbo Stock Issued During Period Value For Warrant And Stock Options Cashless Exercise
StockIssuedDuringPeriodValueForWarrantAndStockOptionsCashlessExercise
21000
nwbo Stock Issued During Period Value For Warrant And Stock Options Cashless Exercise
StockIssuedDuringPeriodValueForWarrantAndStockOptionsCashlessExercise
34000
nwbo Reclassification Of Warrant Liabilities Related To Warrants Exercised For Cash
ReclassificationOfWarrantLiabilitiesRelatedToWarrantsExercisedForCash
22625000
nwbo Reclassification Of Warrant Liabilities To Stockholders Deficit Non Cash Investing And Financing Activities
ReclassificationOfWarrantLiabilitiesToStockholdersDeficitNonCashInvestingAndFinancingActivities
76258000
nwbo Adjustment To Additional Paid In Capital Reclassification Of Cashless Warrants Exercised
AdjustmentToAdditionalPaidInCapitalReclassificationOfCashlessWarrantsExercised
26800000
nwbo Reclassification Of Investor Advances To Convertible Notes Payable
ReclassificationOfInvestorAdvancesToConvertibleNotesPayable
1163000
nwbo Reclassification Of Investor Advances To Stockholders Deficit
ReclassificationOfInvestorAdvancesToStockholdersDeficit
1203000
nwbo Issuance Of Common Stock And Warrants For Conversion Of Debt And Accrued Interest Received
IssuanceOfCommonStockAndWarrantsForConversionOfDebtAndAccruedInterestReceived
17484000
nwbo Issuance Of Common Stock And Warrants For Conversion Of Debt And Accrued Interest Received
IssuanceOfCommonStockAndWarrantsForConversionOfDebtAndAccruedInterestReceived
7054000
nwbo Issuance Of Convertible Preferred Stock In Lieu Of Debt Redemption
IssuanceOfConvertiblePreferredStockInLieuOfDebtRedemption
1013000
nwbo Issuance Of Convertible Preferred Stock In Lieu Of Debt Redemption
IssuanceOfConvertiblePreferredStockInLieuOfDebtRedemption
1978000
nwbo Exercise Common Stock Warrants By Debt Redemption
ExerciseCommonStockWarrantsByDebtRedemption
277000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
6536000
nwbo Capital Expenditures Included In Accounts Payable
CapitalExpendituresIncludedInAccountsPayable
71000
nwbo Capital Expenditures Included In Accounts Payable
CapitalExpendituresIncludedInAccountsPayable
4000
nwbo Reclassification Between Shares Payable And Equity
ReclassificationBetweenSharesPayableAndEquity
250000
nwbo Deemed Dividend Related To Warrant Modification Non Cash Investing And Financing Activities
DeemedDividendRelatedToWarrantModificationNonCashInvestingAndFinancingActivities
1433000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 nwbo Number Of Warrants To Purchase Shares Of Common Stock Reclassified From Liability To Equity
NumberOfWarrantsToPurchaseSharesOfCommonStockReclassifiedFromLiabilityToEquity
141000000
CY2023Q1 nwbo Reclassification Of Fair Value Of Warrant Liability Into Additional Paid In Capital
ReclassificationOfFairValueOfWarrantLiabilityIntoAdditionalPaidInCapital
76300000
CY2023Q3 nwbo Warrant Liability Related To Purchase Shares In Future Raise Of Capital
WarrantLiabilityRelatedToPurchaseSharesInFutureRaiseOfCapital
1000000.0
us-gaap Profit Loss
ProfitLoss
-45100000
us-gaap Payments For Operating Activities
PaymentsForOperatingActivities
36700000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In preparing condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">On an ongoing basis, the Company evaluates its estimates and judgments, including valuing equity securities in share-based payment arrangements, estimating the fair value of financial instruments recorded as derivative liabilities, useful lives of depreciable assets, and whether impairment charges may apply. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the reported amounts of revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates, particularly given the significant social and economic disruptions and uncertainties associated with the ongoing coronavirus pandemic (“COVID-19”) and the COVID-19 control responses.</span></p>
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1200000000
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1700000000
nwbo Modification Of Equity Classified Warrants
ModificationOfEquityClassifiedWarrants
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Modification of Equity Classified Warrants</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A change in the terms or conditions of a warrant is accounted for as a modification. For a warrant modification accounted for under ASC 815, the effect of a modification shall be measured as the difference between the fair value of the modified warrant and the fair value of the original warrant immediately before its terms are modified, with each measured on the modification date. The accounting for incremental fair value of the modified warrants over the original warrants is based on the specific facts and circumstances related to </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">the modification. When a modification is directly attributable to an equity offering, the incremental change in fair value of the warrants is accounted for as an equity issuance cost. When a modification is directly attributable to a debt offering, the incremental change in fair value of the warrants is accounted for as a debt discount or debt issuance cost. For all other modifications, the incremental change in fair value is recognized as a deemed dividend.</p>
CY2023Q3 nwbo Share Receivable Fair Value Disclosure
ShareReceivableFairValueDisclosure
610000
CY2023Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1019000
CY2023Q3 nwbo Contingent Payable Derivative Liability
ContingentPayableDerivativeLiability
8882000
CY2023Q3 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
10250000
CY2023Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
20151000
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
80559000
CY2022Q4 nwbo Embedded Derivative Redemption Option Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeRedemptionOptionFairValueOfEmbeddedDerivativeLiability
807000
CY2022Q4 nwbo Contingent Payable Derivative Liability
ContingentPayableDerivativeLiability
8668000
CY2022Q4 nwbo Share Liability
ShareLiability
678000
CY2022Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
90712000
nwbo Fair Value Liabilities Transfer Between Levels Amount
FairValueLiabilitiesTransferBetweenLevelsAmount
0
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
90712000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
508000
nwbo Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Debt Redemption
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDebtRedemption
-1262000
nwbo Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Reclassification For Warrants Exercised For Cash
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationForWarrantsExercisedForCash
76258000
us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
-4409000
CY2023Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
19541000
CY2023Q3 nwbo Warrant Liability Related To Purchase Shares In Future Raise Of Capital
WarrantLiabilityRelatedToPurchaseSharesInFutureRaiseOfCapital
1000000.0
CY2023Q1 nwbo Reclassification Of Fair Value Of Warrant Liability Into Additional Paid In Capital
ReclassificationOfFairValueOfWarrantLiabilityIntoAdditionalPaidInCapital
76300000
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
2300000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1622000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3361000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2833000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9741000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
2600000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
0.51
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
0.65
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y4M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P3Y10M24D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.84
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.99
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.045
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.033
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
6200000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y10M24D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
301263000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.34
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
135225000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
20220000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.51
nwbo Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm
P6Y3M18D
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
2507000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.45
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
300000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0.83
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
318676000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.34
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y3M18D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
180794000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
281209000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
0.33
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y3M18D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
163974000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
20200000
nwbo Share Based Compensation Arrangement By Share Based Payment Award Period Of Notice For Exercising Any Option
ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodOfNoticeForExercisingAnyOption
P61D
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16751000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13418000
us-gaap Depreciation
Depreciation
1100000
us-gaap Depreciation
Depreciation
900000
CY2023Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
34367000
CY2023Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1430000
CY2023Q3 us-gaap Long Term Debt
LongTermDebt
32937000
CY2022Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
22454000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1732000
CY2022Q4 nwbo Fair Value Of Embedded Conversion Option
FairValueOfEmbeddedConversionOption
807000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
21529000
us-gaap Extinguishment Of Debt Amount
ExtinguishmentOfDebtAmount
1300000
nwbo Accrued Share Liabilities
AccruedShareLiabilities
500000
us-gaap Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost
GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost
3500000
CY2023Q3 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
800000
CY2023Q3 us-gaap Interest And Debt Expense
InterestAndDebtExpense
1700000
CY2022Q3 us-gaap Interest And Debt Expense
InterestAndDebtExpense
500000
CY2022Q3 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
600000
us-gaap Interest And Debt Expense
InterestAndDebtExpense
4000000.0
us-gaap Interest And Debt Expense
InterestAndDebtExpense
4800000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2000000.0
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2100000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
500497000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
472218000
nwbo Percentage Of Margin
PercentageOfMargin
0.15
nwbo Ancillary Services Agreement Additional Term Of Agreement
AncillaryServicesAgreementAdditionalTermOfAgreement
P12M
nwbo Payment Of Milestones In Cash
PaymentOfMilestonesInCash
3500000
nwbo Amount Recognized And Expensed Related To Current Cash Component
AmountRecognizedAndExpensedRelatedToCurrentCashComponent
1000000.0
nwbo Number Of Milestones Completed
NumberOfMilestonesCompleted
2
nwbo Partial Payment For Milestone Completed
PartialPaymentForMilestoneCompleted
2500000
nwbo Shares Issued For Completion Of Milestone
SharesIssuedForCompletionOfMilestone
4.5
CY2023Q3 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
3200000
nwbo Stock Based Compensation Related To Achieved Milestone
StockBasedCompensationRelatedToAchievedMilestone
600000
CY2022 nwbo Stock Based Compensation Related To Achieved Milestone
StockBasedCompensationRelatedToAchievedMilestone
2600000
CY2023Q3 us-gaap Area Of Land
AreaOfLand
88000
CY2023Q3 us-gaap Sublease Income
SubleaseIncome
36000
us-gaap Sublease Income
SubleaseIncome
108000
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1200000000
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1700000000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
nwbo Proceeds From Outstanding Warrant Exercises Including Investor Advances
ProceedsFromOutstandingWarrantExercisesIncludingInvestorAdvances
2800000
CY2022 nwbo Proceeds From Investor Advances
ProceedsFromInvestorAdvances
1200000
nwbo Stock Issued During Period Shares Warrant Exercises
StockIssuedDuringPeriodSharesWarrantExercises
12400000
nwbo Number Of Options Cash Less Exercise
NumberOfOptionsCashLessExercise
2500000
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
141048000
CY2022Q4 nwbo Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
0.31
CY2022 nwbo Class Of Warrant Or Right Outstanding Remaining Contractual Term
ClassOfWarrantOrRightOutstandingRemainingContractualTerm
P1Y1M28D
nwbo Number Of Warrants Warrants Exercised For Cash
NumberOfWarrantsWarrantsExercisedForCash
12447000
nwbo Weighted Average Exercise Price Exercised For Cash
WeightedAverageExercisePriceExercisedForCash
0.22
nwbo Number Of Warrants Warrants Cashless Exercise
NumberOfWarrantsWarrantsCashlessExercise
22907000
nwbo Weighted Average Exercise Price Warrants Cashless Exercise
WeightedAverageExercisePriceWarrantsCashlessExercise
0.20
nwbo Class Of Warrant Or Right Expired
ClassOfWarrantOrRightExpired
250000
nwbo Class Of Warrant Or Right Expired Weighted Average Exercise Price
ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice
1.36
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
105444000
CY2023Q3 nwbo Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
0.32
nwbo Class Of Warrant Or Right Outstanding Remaining Contractual Term
ClassOfWarrantOrRightOutstandingRemainingContractualTerm
P1Y11M1D
nwbo Class Of Warrant Or Right Extended In Suspension
ClassOfWarrantOrRightExtendedInSuspension
100000000
nwbo Share Based Payment Arrangement Plan Modification Associated With Debt Financing As Additional Debt Discount
ShareBasedPaymentArrangementPlanModificationAssociatedWithDebtFinancingAsAdditionalDebtDiscount
800000
nwbo Deemed Dividend Related To Warrant Modification
DeemedDividendRelatedToWarrantModification
1400000
CY2023Q3 us-gaap Lease Practical Expedient Lessor Single Lease Component
LeasePracticalExpedientLessorSingleLeaseComponent
true
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
4500000
CY2023Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P20Y
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4000000.0
us-gaap Operating Lease Cost
OperatingLeaseCost
633000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
62000
us-gaap Variable Lease Cost
VariableLeaseCost
10000
us-gaap Sublease Income
SubleaseIncome
108000
us-gaap Lease Cost
LeaseCost
597000
us-gaap Operating Lease Payments
OperatingLeasePayments
691000
us-gaap Operating Lease Cost
OperatingLeaseCost
643000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
56000
us-gaap Variable Lease Cost
VariableLeaseCost
9000
us-gaap Sublease Income
SubleaseIncome
110000
us-gaap Lease Cost
LeaseCost
598000
us-gaap Operating Lease Payments
OperatingLeasePayments
689000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths
228000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
815000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
610000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
610000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
610000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
6692000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
9565000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
5062000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
4503000
CY2022Q3 nwbo Litigation Settlement Waiver Of Penalty
LitigationSettlementWaiverOfPenalty
135000
CY2022Q3 nwbo Litigation Settlement Waiver Of Penalty
LitigationSettlementWaiverOfPenalty
143000
CY2023Q3 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
377000
CY2023Q3 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
399000
CY2023Q3 us-gaap Former Gain Contingency Recognized In Current Period
FormerGainContingencyRecognizedInCurrentPeriod
4600000
CY2023Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001410578-23-002304-index-headers.html Edgar Link pending
0001410578-23-002304-index.html Edgar Link pending
0001410578-23-002304.txt Edgar Link pending
0001410578-23-002304-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nwbo-20230930.xsd Edgar Link pending
nwbo-20230930x10q.htm Edgar Link pending
nwbo-20230930xex31d1.htm Edgar Link pending
nwbo-20230930xex32d1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
nwbo-20230930_cal.xml Edgar Link unprocessable
nwbo-20230930_def.xml Edgar Link unprocessable
nwbo-20230930_lab.xml Edgar Link unprocessable
nwbo-20230930_pre.xml Edgar Link unprocessable
nwbo-20230930x10q_htm.xml Edgar Link completed
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending